Skip to content

Iliac Vein Stenting in Advanced Chronic Venous Insufficiency

Randomized Double-blind Trial Between Clinical and Endovascular Treatment in Patients With Advanced Chronic Venous Insufficiency and Iliac Venous Obstruction

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02149212
Enrollment
50
Registered
2014-05-29
Start date
2013-02-28
Completion date
2014-07-31
Last updated
2014-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cockett Syndrome, Iliac Vein Obstruction, May-Thurner Syndrome

Keywords

Iliac, Vein, Stent

Brief summary

About 90 % of vascular symptoms affecting the lower limbs consist of venous diseases. Its highest incidence occurs from the second decade of life, affecting significantly the economically active population. Chronic Venous Insufficiency treatment aims to relieve symptoms, treat and prevent complications, prevent recurrences and provide cosmetic satisfaction with minimal side effects. It's current treatment includes some classic postural measures (leg elevation), elastic stockings and bandages compression therapy and possible medication (phlebotonics). The results in the medium and long term are unfavorable, since a large number of patients do not get better or evolves with recurrence of symptoms. Nowadays many, no prospective , not randomized , international studies have shown favorable results with endovascular treatment of obstruction in the iliac vein territory in patients with advanced Chronic Venous Insufficiency . The purpose of this prospective, double-blinded randomized study is to evaluate the results obtained with endovascular treatment, through the use of angioplasty and stenting in this group of patients when compared with clinical treatment .

Interventions

Aminaftone -- 75 mg BID

DEVICEStent

Iliac Vein Stenting

PROCEDURELimb elastic compression support

CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages

PROCEDUREUnna boot dressing

CEAP 6 \> Unna boot dressing

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
Instituto Dante Pazzanese de Cardiologia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Advanced Chronic Venous Insufficiency (CEAP 3-6) submitted to clinical treatment for at least 1 year with no response. * Subject must be \> 18 and \< 80 years of age * Willing to participate in and able to understand, read and sign the informed consent document before the planned procedure * On duplex ultrasound: patent common femoral vein, and patent deep femoral vein, and/or femoral vein of the study leg

Exclusion criteria

* Subject cannot or will not provide written informed consent * Previous venous stent implantation involving the study leg or inferior vena cava * Previous venovenous bypass surgery involving the study leg * Known metal allergy precluding endovascular stent implantation * Known reaction or sensitivity to iodinated contrast that cannot be managed with premedication * Subjects who are pregnant (women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment * Acute deep venous thrombosis involving either leg * Known history of chronic total occlusion of the common femoral vein of the study leg. * Known history of thrombophilia (e.g., protein C or S deficiency, anti-thrombin III deficiency, presence of lupus anticoagulant, etc.) * Venous compression caused by tumor encasement * Venous outflow obstruction caused by tumor thrombus * Life expectancy of less than 6 months * Lower Extremity Arterial Insufficiency * Elevated baseline blood creatinine (value greater than the upper limit of the normal range) * Any concurrent disease or condition that, in the opinion of the Investigator, would make the subject unsuitable for participation in the study; examples include but are not limited to the inability to lie supine for the index procedure (e.g., severe congestive heart failure), thrombocytopenia or other hematological disorders associated with an unacceptable risk of bleeding, implanted orthopedic hardware that precludes proper imaging, etc.

Design outcomes

Primary

MeasureTime frame
Change from baseline in pain on the Pain Visual Analogue Sacale at 6 months6 months
Venous ulcer cicatrization at 6 months6 months

Secondary

MeasureTime frameDescription
Stent integrity at 6 months6 months
Change from the baseline Venous Clinical Severity Score at 6 month6 months
Stent patency at 6 months6 monthsStent patency obtained with treated venous segment Duplex Scanning
Stent position at 6 months6 monthsPelvic X-ray
Change from baseline in SF-36 Quality of Life questionnaire at 6 months6 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026